Delivery Order SPE2DR25D3004-SPE2DR26FXTX0
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $32,674.07 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on January 7, 2026, with an ultimate completion date of January 8, 2026. This firm fixed-price contract, which was not set aside for any specific business classification, represents a task order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX). The parent company, Cencora, Inc. (doing...
- The Defense Logistics Agency awarded a delivery order valued at $10,807.47 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on January 8, 2026, with an ultimate completion date of January 9, 2026. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., is a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $3,111.66 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packaging) on July 24, 2025, with completion scheduled for July 25, 2025. This is a firm fixed price, non-set-aside delivery order executed by the prime contractor, whose corporate office is located in Conshohocken, Pennsylvania. AmerisourceBergen is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement,...
- The Defense Logistics Agency awarded a delivery order valued at $26,892.34 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on January 7, 2026, with an ultimate completion date of January 8, 2026. This non-set-aside, competitively awarded contract utilizes firm fixed-price pricing and represents a task order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) with a ceiling value of $6,558.40. Issued on November 14, 2025, with an ultimate completion date of November 17, 2025, this firm fixed-price delivery order represents a competitively awarded, non-set-aside procurement. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose) valued at $3,111.66 under a firm fixed-price contract. The award, announced on August 6, 2025, with an ultimate completion date of August 7, 2025, represents a non-competitive, non-set-aside delivery order. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order falls...
- The Defense Logistics Agency awarded a delivery order valued at $4,724.33 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on January 12, 2026, with an ultimate completion date of January 13, 2026. This is a firm fixed-price, non-set-aside contract performed at the contractor's headquarters in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $17,740.56 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on January 9, 2026, with a completion date of January 12, 2026. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The award is issued under AmerisourceBergen's parent company Cencora, Inc.'s Indefinite Delivery Contract with DLA Troop Support Medical, a comprehensive pharmaceutical supply vehicle valued at...
- The Defense Logistics Agency awarded a delivery order valued at $3,188.86 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packaging) on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat...
- The Defense Logistics Agency awarded a delivery order valued at $108,228.44 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on January 12, 2026, with an ultimate completion date of January 13, 2026. This firm fixed-price, non-set-aside contract is performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop...
- SPE2DR25D3004Indefinite Delivery Contract
- SPE2DR25D3004-SPE2DR26FXTX0Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,279.20 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packaging) on January 13, 2026, with a completion date of January 14, 2026. This non-set-aside, competitively awarded contract was issued as a firm fixed-price delivery order and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems. This delivery order was issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 2026. The prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the contractor to supply a vast range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. RINVOQ (upadacitinib) is a JAK inhibitor used to treat rheumatoid arthritis and other inflammatory conditions, reflecting the breadth of specialty medications included within the DLA's pharmaceutical prime vendor program that serves military treatment facilities, the Defense Health Agency, and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.3k | 1/12/26 |